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CHAPTER ONE
LITERATURE REVIEW
Statement of the Problem
Parkinson’s disease (PD) is the second most prevalent neurodegenerative disorder
globally. PD patients exhibit multiple debilitating symptoms, notably movement-related
disorders, as well as cognitive and behavioral problems[1]. It affects 1-2% of the
population over the age of 50 with a current estimation of 1.5 million in the United States
alone[2]. The pathological hallmark of PD is the loss of dopaminergic neurons of the
substantia nigra pars compacta (SNpc). The loss of these neurons underlies the movement
related disorders in PD patients. Current treatments of PD do not affect the pathological
mechanisms in which the disease progression occurs [3, 4].
Lewy bodies and Lewy neurites (LB/LN) are found in the cells of the substantia
nigra pars compacta. They are considered a histological hallmark of Parkinson’s disease.
LB/LN are somewhat spherical structures that displace other cellular components (Fig 1).
Mutated/aggregated forms of the protein Α-syn have been identified as the major protein
component of LB/LN formed during PD progression[5]. Numerous studies have shown
that the duplication, triplication and/or mutations of the α-syn gene are the cause of PD
development and progression in affected individuals [6-9]. These pathological α-syn
proteins are able to transfer between cells thus spreading their pathology [10]. The
1
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pathway in which these α-syn entered these uninfected cells has been unknown,
until recently.

Figure 1. Lewy Bodies are a histological hallmark of Parkinson’s Disease. Lewy
bodies are spherical composites of mutated and aggregated forms of the protein α-syn.
They are found in the substania nigra of individuals who suffer from Parkinson’s Disease.
This figure is an H & E stain from Ella Bossy-Wetzel (2004) [11].

Additionally, evidence of mitochondrial dysfunction, increases in the production
of Reactive Oxygen Species (ROS) and decreases in antioxidant production in PD
patients and PD animal models have also been clearly documented[12-14]. These finding
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are correlative since mitochondrial dysfunction has been shown to increase ROS
production[15]. This increase in ROS in patients with PD is believed to be the underlying
cause of cell dysfunction and cell death. It has been theorized that the presence of
pathological forms of α-syn are the cause of these physiological signs of mitochondrial
dysfunction. Therefore, it was pertinent to identify the pathway in which the pathological
forms of α-syn entered uninfected cells.
To determine if pathological α-syn enters uninfected cells through endocytosis,
the cytosolic protein Gal3 was utilized to visualize the colocalization of α-syn with
ruptured vesicles in vitro [16](Fig 2). Gal3 is a lectin protein present diffusely throughout
the cell cytosol that binds the β-galactoside sugars on the inner leaflet of the lysosome
[17]. Once the pathological α-syn ruptures the lysosomal vesicle, the β-Galactoside
sugars are exposed to the cytosol allowing the cytosolic Gal3 to bind and aggregate on
the inner leaflet. Although pathological α-syn has been shown to rupture lysosomes in
vitro, its ability to rupture lysosomes or endosomes has yet to be demonstrated in vivo.
We hypothesize that the utilization of Gal3 as a marker of ruptured vesicles in vivo will
allow us to determine whether pathological forms of α-syn cause the rupture of vesicles
in vivo.

4

Figure 2. Cytosolic Galectin 3 can be utilized as a marker of ruptured vesicles in
vitro. Gal3 has a low affinity for the B-galactosides on the inner leaflet of endosomes.
When the membrane of the endosome ruptures the cytosolic Gal3 can enter the vesicle
and bind the B-galactosides on the inner leaflet. Therefore, when α-syn ruptures the
vesicle membrane the colocalization of the Gal3 and α-syn can be observed. This figure
was provided by D. Freeman [16].

The Epidemiology of Parkinson’s Disease.
PD poses an increasingly large burden both socially and economically on many
societies with aging populations. PD pathogenesis causes the development of crippling
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symptoms in affected individuals. The development of the classic motor control related
signs of PD is the primary base for diagnosis. Unfortunately, development of these signs
indicates the disease has caused significant damage to the dopaminergic neurons of the
SNpc[4]. There is currently no approved treatment for PD that targets a component in the
etiology of PD. Genetic risk factors for PD development include both inheritable and
sporadic gene mutations. These mutations have been the focus of a majority of research
pertaining to PD[18].
PD is clearly an age related disease. Epidemiological studies have shown a rare
occurrence of PD before 50 years. The prevalence of the disease increases significantly
with age. PD was diagnosed in nearly 4% of the highest age group (80yrs+)[19]. The
annual economic impact of PD in the United States is estimated at $10.8 billion. The
annual direct medical cost to an affected individual is between $10,043 and $12,491.
These are more than double the annual amount spent on patients without the disease.
Nursing home care accounts for a large portion of the patients total direct medical cost.
The development of motor control dysfunctions caused by PD forces many patients to
enter nursing home care[20, 21].
PD causes patients to develop multiple behavioral and motor control
dysfunctions. Behavioral problems include the development of depression, anxiety, fear
or isolation. Dementia develops in about 25-40% of patients with PD[22]. Dementia
seems largely responsible for the reduced life expectancy of patients with PD. Motor
control dysfunctions are considered the classic signs of a PD development. The
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developments of resting tremors, bradykinesia, rigidity, or postural imbalance are the
primary signs used to diagnose PD in patients. Further, the physician will also observe
the severity of your response to drugs used to treat PD as a diagnostic method. Since the
development of these motor control problems is indicative of significant loss to the
dopaminergic neurons in the SNpc patients whom are diagnosed are later in the stages of
PD progression[4]. This is a common scenario since there aren’t any diagnostic lab tests
for PD.
The current approved treatments for PD do not inhibit the mechanism in which
PD causes its pathological effects. This is greatly due to the limited amount of knowledge
of PD etiology. Most treatments for PD attempt to restore the proper levels of the
neurotransmitter dopamine by increasing dopamine levels. L-dopa is commonly given to
patients diagnosed with PD. L-dopa is the precursor to dopamine. Dopamine is unable to
cross the blood brain barrier (BBB) and enter the brain cavity. L-dopa is able to cross the
BBB and enter the brain cavity. Once L-dopa enters the brain cavity it is metabolized to
produce dopamine. The effectiveness of this treatment decreases overtime and patients
symptoms will continue to worsen after prolonged use[23, 24]. Other drug therapies
inhibit the degradation of dopamine and reduce the effects of acetylcholine, a
neurotransmitter that can cause a drop in dopamine levels[25]. Deep brain stimulation
(DBS) has recently been implemented as a procedure that can provide dramatic
improvements in many patients’ symptoms. In this procedure, a wire is placed in a
specific location deep within the brain. An electric current is then induced in the wire
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thus stimulating the brain. The mechanism in which DBS works through is not
completely understood[26].
Risk factors for developing PD have been extensively researched. These studies
have attempted to identify the non-genetic and genetic risk factors for PD. The discovery
of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and its damaging effects on the
dopaminergic neurons in the SNpc led to the hypothesis that exposure environmental
toxins may be a risk factor of PD[27]. Evidence consistently points towards a positive
association between presticide exposure and PD risk[28]. Multiple epidemiological
studies have shown a reduced risk of PD among cigarette smokers[29]. The biological
basis that may underlie this association is still poorly understood. Caffeine consumption
was shown to significantly decrease PD risk according to a meta-analysis based on eight
case-control studies and five cohort studies. Caffeine is an inhibitor of the adenosine A2
receptor and improves motor deficits in a mouse model of PD[30]. Studies have also
shown that higher intake of polyunsaturated fatty acids significantly reduce PD risk[31].
Genetic risk factors for PD have been extensively researched since the discovery
of monogenetic mutations that have been shown to correlate with higher risk for PD.
These mutations are considered either inheritable or idiopathic (sporadic). The former
mutations clearly operate under Mendelian inheritance. These forms of mutations are
estimated to cause about 10% of PD cases. Mutations in the gene for the protein α-syn,
and other proteins that are involved in cellular protection against oxidative stress,
mitochondrial dysfunction are among the mutations known. The sporadic mutations do
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not operate under Mendelian inheritance[32]. They are thought to result from complex
interactions between environmental and genetic factors. Genes associated with dopamine
metabolism, mitochondrial metabolism, detoxification, other neurodegenerative diseases,
and familial PD are commonly studied candidates for mutation that cause sporadic PD
development in patients.
Synucleopathies
Pathology
James Parkinson first described a neurodegenerative disease condition he called
“shaking palsy” in 1817. He described individuals exhibiting tremors, rigidity, and
considerable debilitations in motor control[33]. PD pathology is defined by a loss of
dopamine producing neuronal cells in the SNpc and the presence of LB/LN. These
dopaminergic neurons of the SNpc indirectly play a critical role in fine motor control and
learned responses to stimuli. Dopamine modulates neuronal synaptic activity which is
needed for fine and gross motor control. Low dopamine levels in the brain, caused by the
dopaminergic neuron death in PD, result in stiffness with reduced and slowed
movement[3, 34].
The LB was first described by Friederich Lewy in 1912 in substantia innominata
samples from individuals that exhibited Parkinsonism-like symptom [5]. Its biochemical
composition remained unknown until 1997. Soon after the discovery of a point mutation
in the α-syn gene as a cause for inheritable PD, α-syn was found to be the major
component of LB/LN in LB/LN forming synucleopathies such as PD and dementia with
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lewy bodies (DLB)[6-8]. The filamentous glial and neuronal inclusions of multiple
system atrophy (MSA) have also been found to be made of α-syn [35].

α-syn uclein
The first synuclein nucleotide and amino acid sequences were reported by
Maroteaux et al. in 1988. The protein received its name due to its localization in the
presynaptic nerve terminals and portions of the nuclear envelope[36]. Following studies
have failed to confirm a nuclear localization. Two other homologues of this original
synuclein have been discovered subsequently[36-38]. These synucleins have thusly been
named α-syn , Β synuclein, and gamma synuclein. Β synuclein and Gamma synuclein
have not shown any correlation with neurodegenerative disease to date.
α-syn is an amphipathic protein that has little secondary structure. This structure
allows for a high level of heat-stability[39]. Structural research indicates that the
intrinsically unstructured α-syn forms an alpha helical confirmation at the N-terminal in
the presence of cellular membranes. Unique to α-syn is a central hydrophobic region
known as the non-B-amyloid component (NAC) [39-41](Fig 3). Studies pertaining to
Alzheimer’s disease indicate this region is essential for α-syn aggregation. Deletion of
this region has confirmed the role of the NAC in following studies. α-syn can bind lipid
membranes, and selectively inhibits phosopholipase D2. Phosopholipase D2 localizes to
the plasma membrane where it plays a possible role in signal-induced cytoskeletal
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regulation and endocytosis[42-45]. These observations lead many to believe α-syn may
have a role in regulating vesicular transport processes.

Figure 3. Diagram of Alpha Synuclein. α-syn contains a highly conserved amphipathic
region that forms an alpha helical structure in the presence of a lipid membrane (1-60).
Α-syn also has a hydrophobic non-B-amyloid component (NAC) that is unique to α-syn
and facilitates aggregation (61-95). Α-syn also has an acidic C-terminal.

Pathological Alpha Synuclein
In 1995, Polymeropoulos et al. established a genetic link between L-Dopa
responsive parkinsonism with Lewy body formation in a large Italian family and
chromosome 4q21-23. Deletion of these genes proved to cause debilitating mental
disfunction and development. In 1997, further investigation discovered a point mutation
in the α-syn gene in this family and three greek families that shared a common founder
with the Italian family. In this A53T α-syn mutation alanine (A) residue 53 is changed to
threonine (T)[6]. The relevance of α-syn within PD development was controversial since
many rodents and zebra finch carry this mutation. This was later settled after the
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discovery of another point mutation in the α-syn gene in a German family with
inheritable PD. In this A30P α-syn mutation A residue 30 is changed to Proline (P)[46].
Since residue 30 is A in all species examined the scientific community agreed on the
relevance of α-syn in PD development. Soon after, it was discovered that α-syn was the
major component of LB/LN[6-8]. In 2003, Zarranz et al. reported the discovery of the
third major point mutation in α-syn in a Spanish family that suffered from autosomal
dominant parkinsonism, dementia and visual hallucinations of varying severity. In this
E46K mutation glutamic acid (E) residue 46 is changed to lysine (K). Mice expressing
these mutant α-syn develop neurological symptoms similar to those of PD[47].
Due to the abundance of α-syn aggregation in the pathology of Parkinson’s
disease a number of studies have investigated the amino acids of α-syn that are critical to
aggregation in vitro. The central hydrophobic region of α-syn the NAC was found to be
essential for α-syn aggregation. The deletion of residues within the NAC region
prevented α-syn aggregation in vitro[40, 41]. In a transgenic Drosophila model with this
α-syn construct, there was no evidence of large aggregates or oligomeric species of αsyn in these animals and no loss of tyrosine hydroxylase-positive neurons. Transgenic
Drosophila models with increased α-syn aggregation exhibited increased neurotoxicity
and loss of tyrosine hydroxylase positive neurons[48, 49].
The animal models of PD that have been developed were either neurotoxin
induced or through the development of a transgenic animal. These models don’t fully
recapitualate the dopminergic neuron degeneration, motor deficits, and the LB/LN
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accumulations found in PD pathology[50, 51]. In 2012, Luk et al. reported the initiation
of Parkinson-like neurodegeneration in non-transgenic mice given intracranial
inoculations with synthetic α-syn fibrils. The fibrils were shown to seed aggregation of
endogenous wt α-syn

, transmit pathological α-syn

to other healthy cells, causes death

of dopaminergic neurons and cause motor deficits in mouse model[10].
Reactive Oxygen Species (ROS)
In both sporadic and genetic PD, oxidative stress is thought to be the underlying
mechanism that leads to cell dysfunction and death. The SNpc of PD patients have shown
evidence of increased ROS production and decreased antioxidant activity[12-14].
Tyrosine hydroxylase is a known ROS-generating enzyme. This causes greater
susceptibility to cellular damage from oxidative stress in dopaminergic neurons.
Additionally nigral dopaminergic neurons contain iron, which catalyzes the Fenton
reaction and contributes to further oxidative stress. Since the dopaminergic neurons are
highly sensitive to ROS, moderate oxidative stress can result in cell death[13].
Dopamine is normally packaged within cytoplasmic vesicles. When the level of
cytosolic dopamine becomes excessive it is oxidized into Dopamine Quinone due to
ROS. Dopamine Quinone has been shown to covalently modify proteins whose
dysfunction has been linked to PD pathophysiology. Α-syn is one of the particular
proteins that are modified by Dopamine Quinone. This modification of α-syn promotes
the protofibril formation of α-syn . This protofibril form of α-syn is thought to be
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pathogenic. Dopamine Quinone also causes mitochondrial dysfunction, as well as the
inactivation of DA transporters and tyrosine hydroxylase[52, 53].
Multiple mutations in genes of mitochondrial proteins were discovered in the
familial forms of PD[32]. Mitochondrial dysfunction is a common cause of dramatic
increases in ROS production in multiple cell types. Neurons utilize mitochondrial aerobic
respiration for ATP production. Hydrogen peroxide and super oxide radicals are
byproducts formed during oxidative phosphorylation in the mitochondria. The increase in
ROS production due to mitochondrial dysfunction can cause oxidative stress which can
cause peroxidation of the mitochondria-specific lipid cardiolipin. This results in the
release of cytochrome c into the cytosol, which initiates the apoptosis pathway. MPTP
was discovered to cause Parkinson’s Disease –like symptoms in individuals by causing
mitochondria dysfunction in neurons of the SNpc. It achieves this by causing damage to
Complex I of the electron transport chain. This causes leakage of electrons, which thus
causes ROS generation. Α-syn has been shown to interact with mitochondrial
membranes and inhibit Complex I[15] (Fig 4).
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Figure 4. MPTP damages Complex I of the electron transport chain. MPTP mimics the
effects of Parkinson’s Disease by damaging Complex I of the electron transport chain. This
causes a leakage of electrons that in turn leads to increased ROS production.

Loss of neuronal cells due to neuroinflammation is common in organisms with
PD. The neuroinflammatory response is controlled by microglia. Microglia are innate
immune cells located in the central nervous system. They are the main immune
responsive cells in the central nervous system. Microglia are considered to be “resting”
when they are not “activated” by chemical stimulants generated due to brain damage
and/or the presence of an antigen. Once activated the microglia release free radicals such
as nitric oxide and superoxide while functioning as an innate responsive cell. These free
radicals contribute to the oxidative stress of the microenvironment. The SNpc of sporadic
and familial PD patients have increased levels of activated microglia[54]. It has been
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shown that the addition of aggregated α-syn to a primary mesencephalic neuron-glia
culture causes activation of microglia and dopaminergic neurodegeneration. This
cytotoxicity does not occur when microglia are absent from the culture[55]. Neuron
derived α-syn stimulates astrocytes to produce inflammatory modulators which augment
microglial chemotaxis, activation, and proliferation[56]. Currently, there is no therapy
clinically available that delays the neurodegenerative process.
Ruptured Vesicles
Evidence indicates that pathological α-syn has the ability to be transferred from
an infected neuronal cell to a healthy neuronal cell[57-60]. It has been hypothesized that
the pathological forms of α-syn enter the cells via endocytosis. This theory called into
question the method in which α-syn escapes the vesicle in order to enter the cytosol.
Previous work with Adenovirus Type 5 has shown that the rupturing of lysosomes in
cells caused by adenovirus infection leads to Cathepsin B- Dependent Mitochondrial
Stress and the production of ROS[15]. Since similar physiological signs are present in the
cells of PD patients, our lab suggested that α-syn enter the cell via endocytosis and
ruptures from lysosomes. These hypotheses were later confirmed through
experimentation. α-syn aggregates were shown to localize to areas of vesicle rupture in
vitro (Fig 2). These ruptured vesicles were shown to be positive for lysosomal associated
membrane protein-2 (LAMP2). This indicates that the vast majority of vesicles ruptured
by α-syn are lysosomes[16]. Previous studies of the α-syn protein have shown that low
pH environments cause α-syn to undergo a conformational change[61]. Therefore, the
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low pH environment of the lysosome may cause a conformation change in the α-syn
which allows it to rupture the vesicle and escape into the cytoplasm. The rupture of
lysosomes has been associated with an increase in cellular ROS in cells due to the release
of activated cathepsins contained within the lysosome. Furthermore, α-syn induces a
cathepsin B dependent increase in ROS in infected cells[16].
Galectin 3
Galectins are a family of evolutionary conserved animal lectins that bind βgalactosides. They are found ubiquitously in mammals, invertebrates and fungi[62].
Galectins have considerable immunoregulatory activities including regulation of immune
homeostasis[63]. All galectins exhibit sequence homology in the carbohydrate
recognition domain (CRD) but they have different affinities for different saccharide
ligands[64]. Gal3 (Gal3) is a structurally unique member of the galectin family and
exhibits both extracellular and intracellular functions. It is important to note that Gal3
doesn’t posses a secretion signal peptide that would direct transport through the classical
endoplasmic reticulum-Golgi apparatus secretory pathway. Gal3 contains a single CRD
and an elongated N-terminus compared to other galectin members (Table 1). This
elongated N-terminus plays a role in protein oligomerization and is believed to participate
in the interaction with other intercellular proteins. Therefore Gal3 can interact with both
carbohydrates and proteins[65, 66]. At low concentrations, Gal3 is a monomer that can
potentially form oligomers upon binding to multivalent saccharides. Gal3 has the ability
to crosslink cell surface receptors, thus forming a cluster of ligands into a lipid raft micro-
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domains[67, 68]. Gal3 ability to bind cell surface receptor has been shown to affect
multiple cellular processes including cell-cell adhesion, proliferation, differentiation, and
cytokine secretion[69-72]. Additionally, Gal3 has both a pro- and anti- apoptotic
activities determined by extracellular or intercellular location[73]. Gal3 is now known to
be related the pathophysiology of multiple diseases, including cardiovascular disease,
cancer, asthma, prion infection, rheumatoid arthritis and streptococcus pneumonia
infections. In vivo, an increase in the extracellular concentration of Gal3 has been
measured in the inflammatory setting in animal models. Gal3 levels are currently being
used as an indicator of multiple types of infections and disease conditions in clinical
medicine settings[74-76]. Gal3 was discovered to be regulated at the protein level in
response to IL-1B, and at the mRNA level in response to advanced glycation end
products casein[77]. These findings are consistent with the up regulation of Gal3 during
innate immune activation.
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Table 1. Galectin 3 has a unique structure compared to other members of the
Galectin family. Gal3 is the only chimeric type member of the Galectin family. It
contains one carbohydrate recognition domain and one dimer binding site. Gal3 has a
uniquely elongated N-terminus. This elongated N-terminus is believed to give Gal3
inflammatory regulatory capabilities.

Multiple studies show that Gal3 has a critical role in the process of leukocyte
trafficking, activation and cytokine release[78]. Gal3 was discovered to cause Calcium
influx in monocytes. This calcium influx involves a pertussis toxin-sensitive pathway,
which suggest a G protein-coupled receptor could be a target receptor for Gal3[79]. In
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vitro, Gal3 can cause superoxide release from monocytes and promote the uptake of
apoptotic neurtrophils from monocyte derived macrophages[79-81]. The macrophages of
mice deficient in Gal3 showed reduced phagocytosis apoptotic thymocytes in vitro
compared to wild type mice. Phagocytic clearance of apoptotic thymocytes by peritoneal
macrophages was attenuated in Gal3 deficient mice in vivo[74]. These studies suggest
Gal3 is a pro-inflammatory protein. It is important to mention that recent studies
pertaining to the role Gal3 plays in salmonella infection and asthma have suggested that
Gal3 also acts as an anti-inflammatory protein[82, 83]. These results may not represent
the effect of endogenous Gal3. A large number of in vivo and in vitro studies suggest that
Gal3 is pro-inflammatory.
Within the last 5 years Gal3 has been utilized as a marker of vacuole lysis by
invasive pathogens. Multiple infectious agents, including Shigella bacteria, must evade
the immune system while invading the host. Upon internalization into the host cell the
bacteria lyses the phagosome before it is fused with a lysosome and escapes into the
cytosol[84]. This process was poorly understood since there wasn’t a reliable marker for
ruptured vesicles. Paz and company utilized the affinity that Gal3 has for the βgalactosides sugars on the inner leaflet of the ruptured vesicles to identify ruptured
vesicles. Once the bacteria lysed the vesicle the β-galactoside sugars were exposed to the
cytosol and the cytosolic Gal3. By labeling the Gal3 after bacterial infection Paz and
company were able to reliably identify ruptured vesicles which would have clusters of
oligermerized Gal3 bound to their inner walls[17].
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Photoactivatable Green Flourescent Protein fused to Galectin 3
The utilization of fluorescent proteins, such as green fluorescent protein (GFP),
allows for non-invasive analysis of protein localization and dynamics in living cells[85].
This is achieved by producing a fusion protein with the fluorescent protein and a protein
of interest. This fusion protein can then be expressed in a cell or organism and its
movements can be tracked via fluorescent microscopy. Innovation developed using these
fluorescent proteins include the production of photoactivatable fluorescent proteins
(PFAP)[86]. One such protein created by utilizing GFP is photoactivatable GFP
(PAGFP). When initially expressed PAGFP emits low intensity light. After exposure to
approx. 400 nm wavelength light (UV light) the PAGFP will undergo irreversible
photoconversion causing it to emit light with nearly 100 fold greater intensity (Fig 5).
This photoconversion involves the decarboxylation of Glu222 followed by chromophore
conversion from a neutral to anionic state[86]. PAFP’s introduce a new methodology of
kinetic microscopy of living cells, which was traditionally associated with fluorescence
recovery after photobleaching (FRAP)[87]. It is worth mentioning that some PAFPs
undergo a reversible photoconversion process[88]. These photoactivatable proteins are
also useful when overcoming hindrances to resolution that can develop that can develop
when viewing tissue samples using fluorescent microscopy techniques, such as tissue
autoflourescence [89, 90].
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Figure 5. Photoactivatable green fluorescent protein increases its light intensity by nearly
100 fold after activation with ≈400 nm light (UV light). The photoconversion of
photoactivatable green fluorescent protein is an irreversible process. It is widely used in protein
kinetics studies to track proteins in living models. Prior to exposure to UV light the PAGFP will
emit a low level of fluorescent light. Following exposure PAGFP will increase its fluorescent
light intensity by nearly 100 fold.

CHAPTER TWO
EXPERIMENTAL METHODS
Cell lines and reagents
The human monocyte cell line THP-1 was obtained from the American Type Culture
Collection (ATCC). ATP and phorbol-12-myristate-13-acetate (PMA) were purchased
from Sigma-Aldrich. PMA was used to differentiate Thp-1 monocytes. The THP-1 cells
were maintained in Roswell Park Memorial Institute (RPMI) 1640 media, supplemented
with 10% fetal bovine serum (FBS), 100 IU/ml penicillin, 1mg/ml streptomycin, 1mM
sodium pyruvate and 2 mM glutamine. The human neuroblastoma cell line, SH-SY5Y
was obtained from the American Type Culture Collection (ATCC). SH-SY5Y cells were
maintained in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10%
(FBS)(Hyclone) and 100 IU/mL penicillin, 1mg/mL streptomycin and 10 µg/mL
ciprofloxacin. Cells were maintained in a 37°C incubator with 5% CO2. The mCherrygal3 plasmid was a generous gift from Dr. Christopher Wiethoff. Retroviral vectors and
Lentiviral vectors were generated utilizing transfection of 293T cells with the packaging
plasmids vesicular stomatitis virus glycoprotein (VSV-g), delta nrf and mCherrygal-3.
Transfections were performed using polyethylenimine (PEI) (molecular weight, 25,000;
Polysciences). Supernatants containing these recombinant retroviral 38 vectors were
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collected 48 hours post-transfection and used to transduce SH-SY5Y and THP-1 cells.
Positive transductants were selected with Geneticin/G418.
Alpha Synuclein
Full length α-syn were purchased (rPeptide) and the lyophilized protein was rehydrated in
PBS with 100 mM NaCl immediately upon arrival to a concentration of 1 mg/ml and was
aliquoted and stored at -80°C. In order to generate aggregates, alphα-syn uclein was
incubated for 3 days at 37°C under constant agitation at 300 revolutions per minute (rpm)
followed by storage at -80°C. Aggregates were added at a concentration of 3µg/ml per
the protocol provided by Volpicelli-Daley[91].

Western Blot
Purified proteins were separated via sodium dodecyl sulfate polyacrylamide gel
electrophoresis, (SDS-PAGE), proteins were transferred to nitrocellulose membranes and
detected by incubation with the primary antibody. The monoclonal mouse anti-human
Gal3 antibody from BD Pharmingen was purified from tissue culture supernatant or
ascites by affinity chromatography. Secondary antibody conjugated to HRP (Thermo
Scientific) was used where necessary, and antibody complexes were detected using
SuperSignal West Femto chemiluminescent substrate (Thermo Scientific).
Chemiluminescence was measured using a BioRad ChemiDoc XRS imaging system
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(BioRad). Gal3 values were quantified using Imagj software to perform densitomitry
analysis of the western blot bands.

Animals and Surgery
Young adult Sprague Dawley rats (Charles River Laboratories, Wilmington, MA) were
housed two to a cage with ad libitum access to food and water during a 12 h light/dark
cycle, according to the rules set by the Research Ethical Committee at Rush University
Medical Center. Recombinant adeno associated virus serotype 6 vector
encoding human mutant (A30P) α-syn gene (rAAV6-h-A30P) were prepared and titered
as described previously (Towne et al., 2008). Under halothane anesthesia, 2 μl of the
vector suspension was injected stereotaxically into the right nigral region at 5.3 mm
posterior and 2.3 mm lateral to bregma, 7.7 mm ventral to dura. The needle was kept in
place for an additional 5 min before slowly being withdrawn. At 6 weeks after injection,
animals (rAAV6-h-A30P, n= 10) were perfused through the ascending aorta with
physiological saline, followed by 4% ice-cold paraformaldehyde. The brains were postfixed in the same solution for 2 h, transferred to10%, 20%, 30% sucrose, and sectioned
on a freezing microtome at 40 μm in the coronal plane. All sections were collected and
stored in order in a cryoprotectant solution before processing. All animal experiments had
prior approval from the Institutional Animal Care and Use Committee at Rush University
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Immunofluorescence Microscopy
For in vitro experiments cells were allowed to adhere to Fibronectin (Sigma-Aldrich)
treated glass coverslips and fixed with 3.7% formaldehyde (Polysciences) in 0.1 M
piperazine-N, N'bis(2-ethanesulfonic acid) PIPES buffer at pH 6.8 for 15 min.
For experiments utilizing rat brain tissue slides, primary antibodies to Gal3 and α-syn
were used in their preparation. The monoclonal mouse anti-human Gal3 antibody from
BD Pharmingen was purified from tissue culture supernatant or ascites by affinity
chromatography.
Primary antibodies were secondarily labeled with fluorophore-conjugated mouse antihuman antibodies (Jackson ImmunoResearch). Images were collected with a DeltaVision
microscope (Applied Precision) equipped with a digital camera (CoolSNAP HQ;
photometrics), using a 1.4 numerical aperture (NA) 100X objective lens, and were
deconvolved with SoftWoRx deconvolution software (Applied Precision). Structured
Illumination images were collected on an OMX microscope (Applied Precision) and
deconvolved and reconstructed using SoftWoRx software (Applied Precision). Tiff
images and 3-dimensional reconstructions were generated using Imaris software
(Bitplane).
Image Analysis
Deconvolved images were analyzed for colocalization of PAGFP Galectin-3 (Gal-3) with
mCherry Galecint 3 by use of the Surpass Mode of the Imaris software package
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(Bitplane).
Statistical Analysis
Results are presented as mean + standard error of the mean. Two-sample t-test was used
to compare between different experimental groups. All statistical analyses were
performed using InStat 3.0 (GraphPad Software). p<0.05 was considered statistically
significant.

Densitometry Analysis
Western blots bands were analyzed utilizing ImageJ software. Control levels were
normalized to a value of 100. Variable band values are expressed in comparison to the
normalized control values of 100. Adjustments to Gal3 band values were made in
proportion to the differences in their corresponding actin band values compared to the
actin bands of the control samples.

CHAPTER THREE
RESULTS
Colocalization of Galectin 3 and α-syn observed In vivo
Gal3 is a lectin protein which binds the β-galactosides on the outer leaflet of the cell
membrane and on the inner leaflet of the cellular vesicles. Once a vesicle is ruptured
the Gal3 are able to enter the vesicle and bind the β-galactosides on its inner leaflet.
The colocalization of Galectin3 and α-syn at the site of ruptured lysosomes has been
used to identify part of α-syn ’s pathway of infection. These in vitro data indicate that
α-syn enters the cell through endocytosis and then ruptures from the lysosome in
order to enter the cytosol. In order to visualize this colocalization in vivo, histology
slides were prepared using the brain tissue of rats that were treated with AdenoAssociated-Virus (AAV) vector expressing the pathological α-syn mutant A30P.
These tissue samples were then stained with fluorescent anti-bodies to Gal3 and α-syn
. The histology slides were examined under a fluorescent microscope. Visualization
of α-syn was clear, distinguishable, and isolated within the Cy5 channel. Contrarily,
we were unable to isolate Gal3 in the FitC channel due to bleed through from tissue
autofluorescence. This tissue autofluorescence hindered us from having clear
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resolution of the Gal3. Thus, we weren’t able to visualize with certainty the
colocalization of Gal3 and α-syn in vivo.
Galectin 3 levels increase in rat brain tissue when exposed to pathological alpha
synuclein mutant (A30P)
Increases in Gal3 levels have also been well documented during multiple pathogenic
infections including streptococcus pneumonia and prion infection. We therefore wanted
to determine whether Gal3 levels increased in vivo when a rat brain is exposed to a
pathological mutant of the protein α-syn . Utilizing an A30P α-syn expressing AAV
vector and fluorescent antibodies to A30P α-syn and Gal3 we were able to visualize and
quantify differences in Gal3 levels during infection with pathological α-syn in the rat
brain (Figure 6A). We utilized rat brain tissue that was injected with AAV vector that
wasn’t expressing the A30P α-syn protein as our control group. The level of fluorescent
intensity was indicative of the protein expression levels. Upon evaluation of multiple
brain sections, we found that the levels of Gal3 had significantly increased in the brain of
rats injected with the AAV vector expressing A30P α-syn compared to the levels in the
control rat brains (Figure 6B).
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Figure 6. Galectin 3 levels in Rat Brain tissue treated with AAV expressing
pathological alpha synuclein (A30P). Rat brain tissue sections from rats receiving right
nigral brain injections of AAV expressing pathological α-syn were stained with with
fluorescently labeled antibodies to Gal3 (Green) and α-syn (Red)(A). Gal3 levels in rat
brain tissue tissue treated with AAV expressing pathological α-syn had significantly
higher Gal3 levels (B). Two-sample t-test, *p < 0.005, n = 5 rat brains with 68 brain
regions analyzed.
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Galectin 3 levels increase in neuronal cell line (Sy5y) during treatment with
pathological alpha synuclein aggregates
The brain is composed of multiple cell types. Two cell types which contribute greatly
to the composition of the brain are the Neurons and Glial Cells. The increase in the levels
of Gal3 in rat brain tissue following midbrain injection with virus vector expressing
A30P α-syn beckoned us to determine which cell type was responsible for this increase.
We utilized Sy5y neuroblastoma cells as our neuronal cell line. The Sy5y cells were
treated with pathological α-syn aggregates and harvested at 24, and 48 hour time points.
Gal3 levels were then determined qualitatively by western blot analysis (Figure 7A) and
quantitatively by densitometry analysis (Figure 7B). This allowed us to determine
whether neuronal cells contribute to the increase in Gal3 levels. We found that Sy5y
neuroblastoma cells showed a ≈ 50% increase in intercellular levels of Gal3 after 48
hours of treatment via western blot analysis. Though increases in Gal3 levels were
observed, the basal levels of Gal3 in Sy5y cells were considerably low.
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Gal3

Actin

Figure 7. Galectin 3 levels increase after treatment with alpha synuclein oligomers
in Sy5y cells. Gal3 levels in SY5Y cells increase by approx. 50% after 48 hours of
treatment with α-syn oligomers (B). Cells were harvested at 24 hr and 48 hr time points.
Gal3 levels were analyzed by western blot and quantified using Image J software and
were normalized to control values (A). Control values normalized to 100.

Galectin 3 levels increase in immune cell line (differentiated THP-1 monocytes)
during treatment with pathological alpha synuclein aggregates
With the discovery that our neuronal cell line has low basal levels of Gal3 we then
wanted to analyze the change in the levels of Gal3 in glial cells after treatment with
pathological aggregates of α-syn . Since microglia have been shown to be activated
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during PD progression we wanted to use them as our glial cell model. Differentiated Thp1 monocytes (macrophages) are known to produce large amounts of Gal3 and are widely
utilized in studies of microglia. We utilized differentiated Thp-1 monocytes that were
differentiated in macrophages as our representative glial cell line. Differentiated Thp-1
macrophages are widely accepted as a representative cell line of microglial during
experimentation. Differentiated Thp-1 cells were treated with pathological α-syn
aggregates and harvested at 24, and 48 hour time points. Gal3 levels were then
determined qualitatively by western blot analysis and quantitatively by densitometry
analysis (Figure 8A). This allowed us to determine whether the glial cells are more
likely to be the major contributors to the increase in Gal3 levels than neuronal cell types.
We found that the differentiated Thp-1 monocytes showed a nearly 100 percent increase
in intercellular levels of Gal3 after 48 hours of treatment (Figure 8B). The basal levels of
Gal3 were comparably higher than that of our neuronal cell line making a 100 percent
increase in Gal3 levels substantial.
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Gal3

Actin

Figure 8. Galectin 3 levels increase after treatment with alpha synuclein oligomers.
Gal3 levels in THP-1 cells increase by approx 50% after 48 hours of treatments with αsyn oligomers (A). Cells were harvested at 24 hr and 48 hr time points. Gal3 levels were
analyzed by western blot and quantified using Image J software and were normalized to
control values (B). THP-1 data is representative of three independent experiments.
Control values normalized to 100.

PA-GFP Gal 3 CRD has similar binding properties to fully expressed Galectin 3
In our attempt to use a green fluorescent protein labeled Gal3 (GFP-Gal3) to label
ruptured vesicles in vivo, we were unable to resolve GFP-Gal3 puncta due to tissue
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autoflourescence. We have since utilized the photoactivatable fluorescent protein (PAFP)
,phothoactivatable green flourescent protein (PAGFP) , in order to correctly resolve the
Gal3 in the presence of tissue autoflourescents. This would be done by comparing the
pre- and post- activation photos of the tissue sample and determining which source of
light is being emitted by the PAGFP-GAL3. In order to utilize Gal3 as a marker of
ruptured vesicles in our in vivo studies we want to express the PAGFP-Gal3 protein in
the CNS of a transgenic mouse. Since Gal3 is known to function as an inflammatory
regulator protein, we want to eliminate its inflammatory mediating function before
expressing it in the CNS of a transgenic mouse. We accomplished this by expressing only
the CRD region of Gal3. This would allow the fusion protein to have the same binding
characteristics as the fully expressed Gal3 while alleviating the potential complications
caused by its inflammatory effects. Western blot analysis of the PAGFP-Gal3 CRD
(PAGFP-CRD) confirms that the fusion protein is properly expressed at ≈36 kD
(expected size at 35 kD) (Figure 9B). The PAGFP-CRD is able to be activated through
exposure to ≈400 nm light (Ultra violet light) and undergo photoconversion in vitro thus
causing a nearly ten-fold increase in light intensity emission (Figure 9A). Finally, by
expressing both fully expressed cherry Gal3 and PAGFP-CRD in the same cell we were
able to observe similarities in their binding properties. The data shows that PAGFP-CRD
exhibits identical binding properties to fully express cherry Gal3(chGal3) (Figure 9C).
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Fig 9. PAGFP labelled Galectin 3 CRD exhibits binding properties similar to
Galectin 3. Gal3 CRD binds to β-galactosides in a similar manner as fully expressed
Gal3(C). The antibodies used to label Gal3 CRD and PAGFP appear at the same level
indicating the fusion protein is being expressed intact (B). The PAGFP fused to the
Gal3/CRD emits higher intensity light once activated (A).

CHAPTER FOUR
DISCUSSION
The previous results were gathered while attempting to utilize Gal3 as a marker of
ruptured vesicles in vivo. The progress gained in this study will allow us to test the
hypothesis that pathological forms of α-syn including mutants and oligomers are able to
rupture lysosomes in vivo. This hypothesis was developed using previous work which
showed that α-syn aggregates have the ability to rupture lysosomes in vitro[16]. The
affinity Gal3 has for the Β Galactoside sugars on the inner leaflet of
lysosomes/endosomes has been utilized as a tool for determining pathogen etiology.
Multiple pathogens enter the host cell during infection. It is necessary for these pathogens
to evade the host immune system in order to survive. This is accomplished by the
utilization of multiple evasion techniques and mechanism. One known evasion method
includes endocytosis of the pathogen by the host cell followed by pathogenic vesicle
escape into the cytosol. During the pathogens escape the vesicle is ruptured and the
cytosol is able to access the internal space of the vesicle. This allows Gal3 proteins to
enter the vesicle and bind its’ receptor[17]. While attempting to use Gal3 as a marker of
ruptured vesicles in rat brain tissue that had been exposed to the pathogenic α-syn mutant
A30P we were unable to gain effective resolution of Gal3. This failure was due to the
abundance of tissue autofluorescence. The visualization of the co-localization of the α36
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syn mutant protein and the Gal3 protein is a critical part to the experiment. Since we
were unable accomplish this we had to modify our approach in order to gain enough
resolution of the Gal3 protein. Though we failed to visualize co-localization of the two
proteins, we were able to quantify the levels of Gal3 in A30P treated tissue by use of
fluorescent microscopy. This quantification showed that Gal3 levels were significantly
increased in tissue samples that were exposed to the pathological A30P α-syn protein. It
is well documented that Gal3 levels are increased in multiple disease states including
cardiovascular disease, cancer, asthma, prion infection, rheumatoid arthritis and
streptococcus pneumonia infections[74-76]. Increases in Gal3 levels pertaining to
synucleiopathies such as parkinson’s disease has yet to be documented. Previous work
has indicated that Gal3 is involved in innate immune activation and is regulated at the
protein level by IL-1B, an inflammatory cytokine. This observation correlates with
previous work which indicated an increase in IL-1B levels in the substantia nigra of PD
patients[92, 93]. It also correlates with data that shows α-syn aggregates are able to cause
caspase 1 activation in vitro, thus causing the release of IL-1B[16].
Gal3 is a useful marker of ruptured vesicles largely due to its diffuse distribution in a
cells cytoplasm. In the presence of ruptured vesicles these diffuse proteins aggregate on
the inner leaflet of these ruptured vesicles. These aggregates amplify the signal of the
fluorescently labeled Gal3 distinguishably from that of the diffuse protein. Therefore, a
strong contrast between the signal intensity of the diffuse Gal3 from the aggregated Gal3
proteins is critical to the efficacy of Gal3 as a marker of ruptured vesicles. Consequently,
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an increase in the concentration of diffuse cytosolic Gal3 would diminish the
effectiveness of Gal3 as a marker of ruptured vesicles.
Neurons and Glial cells are two major types of cells present in the composition of the
CNS. Since we are ultimately interested in utilizing Gal3 as a marker of ruptured vesicles
in neuronal cell lines we want to determine whether neuronal cells contribute to the
increase in Gal3 concentrations and, if so, how large is the relative contribution. We
decided to utilize differentiated THP-1 cells as our representative Glial cell line and SHSy5y human neuroblastoma cells as our neuronal cell line. We treated SH-Sy5y human
neuroblastoma cells and differentiated THP-1 human monocyte cells with α-syn
oligomers for up to 48 hours. Western blot analysis showed increases in Gal3 levels in
both cell types. The most significant increases were observed at 48 hours. Though the
Sy5y neuroblastoma cells did show a nearly 50% increase in Gal3 levels their basal Gal3
levels were significantly lower than those of the differentiated human monocyte THP-1
cells. The THP-1 cells exhibited a nearly 100% increase in Gal3 levels following 48
hours of treatment. These results lead us to believe that the neurons are not the major
contributor of Gal3 production in the CNS during pathological α-syn infection.
It is important to note that this α-syn induced increase in Gal3 levels eliminates
the use of endogenous Gal3 as a useful marker of ruptured vesicles in vivo. The newly
expressed Gal3 is released into the cytosol of the infected cell. If the concentration of
Gal3 in the cytosol increases then the contrast between diffuse cytosolic Gal3 and the
aggregated vesicular Gal3 will become less distinguishable. These protein dynamics also
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renders the capability of our software to quantify and calculate fluorescent data
inadequate. The increase in overall Gal3 levels in the cell would cause a considerable
amount of variability in the experiment data. This variability would thus cause imprecise
analysis to be produced.
In order to utilize Gal3 as a marker of ruptured vesicles in vivo we would have to
overcome the loss of resolution due to tissue autofluorescence as well as the increased
cytosolic Gal3 concentrations due to pathological α-syn treatments. We elected to
accomplish this by fusing Gal3 to the fluorescent protein photoactivatable green
fluorescent protein (PAGFP). The fusion protein exhibits expression levels that are not
affected due to α-syn pathology. Examination of the PAGFP-Gal3 protein indicates that
it has the same binding property of endogenous Gal3. Analysis of the PAGFP-Gal3
protein also confirmed its ability to be fluorescently activated when exposed to approx.
400 nm light. This activation causes the fluorescence of the PAGFP to intensify
approximately 100 fold. This change in light intensity allows us to differentiate Gal3
oligomer fluorescence from the autofluoresence of tissue samples.
In order to complete our in vivo studies we will be expressing the PAGFP-Gal3 in
the cells of CNS of a transgenic mouse. Gal3 is known to be an inflammatory regulating
protein[82]. This function is unique to the Gal3 within the Galectin family of proteins.
The uniqueness of the structure of Gal3 is believed to give Gal3 this unique function.
Increasing the expression of an inflammatory regulating protein in the CNS of a
transgenic mouse can cause lower animal viability and even death. In order to alleviate
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this concern, we expressed the homologous CRD region of the Gal3 protein fused to the
PAGFP (PAGFP-CRD). This eliminates the unique structure of Gal3 as well as its’
unique inflammatory regulating function. Analysis of the PAGFP-CRD protein indicates
that it has similar binding properties to Gal3. Analysis of the PAGFP-CRD protein also
confirmed its ability to be fluorescently activated when exposed to approx. 400 nm light.
The PAGFP-CRD will be expressed in the CNS of a transgenic mouse. The
transgenic mouse will be treated with pseudovirus vector expressing a pathological
mutant of α-syn . The brains will then be harvested and prepared to be analyzed by
fluorescent microscopy based on the methods developed by the Kordower lab. We
believe this analysis will provide evidence that the pathological α-syn enters the cell
through endocytosis and ruptures from the vesicle in order to enter the cytosol.
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